Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios
Asset Utilization RatioAssets AverageEBIT MarginEBITDA MarginEBT MarginEnterprise ValueFCF MarginInterest Coverage RatioNet MarginOperating MarginReturn on AssetsReturn on Capital EmployedReturn on SalesTimes Interest Earned

AC Immune (ACIU) EBIT Margin (2016 - 2025)

Historic EBIT Margin for AC Immune (ACIU) over the last 11 years, with Q3 2025 value amounting to 1721.62%.

  • AC Immune's EBIT Margin fell 17501400.0% to 1721.62% in Q3 2025 from the same period last year, while for Sep 2025 it was 1678.03%, marking a year-over-year decrease of 15414500.0%. This contributed to the annual value of 191.8% for FY2024, which is 1705000.0% up from last year.
  • As of Q3 2025, AC Immune's EBIT Margin stood at 1721.62%, which was down 17501400.0% from 1484.53% recorded in Q2 2025.
  • AC Immune's EBIT Margin's 5-year high stood at 1869700.0% during Q4 2022, with a 5-year trough of 862550.0% in Q1 2021.
  • For the 5-year period, AC Immune's EBIT Margin averaged around 40616.7%, with its median value being 3051.09% (2024).
  • Its EBIT Margin has fluctuated over the past 5 years, first skyrocketed by 2000000000bps in 2022, then plummeted by 2000000000bps in 2023.
  • Quarter analysis of 5 years shows AC Immune's EBIT Margin stood at 3956.08% in 2021, then skyrocketed by 47361bps to 1869700.0% in 2022, then plummeted by -100bps to 1082.87% in 2023, then tumbled by -51bps to 1637.47% in 2024, then fell by -5bps to 1721.62% in 2025.
  • Its EBIT Margin was 1721.62% in Q3 2025, compared to 1484.53% in Q2 2025 and 1956.57% in Q1 2025.